TAILIEUCHUNG - CLINICAL AND MOLECULAR ADVANCES IN ANKYLOSING SPONDYLITIS

Ankylosing Spondylitis (AS) was first described possibly at the end of the XVII century by Buckley (1931) and Connor, but it was only recognized after the radiologic descriptions of Bechterew, Strumpell and Marie, during the XIX century. In 1964 the American Rheumatism Association classified AS as a distinct disease. About forty years ago (1973), Schlosstein and Brewerton published simultaneously but independently the association of AS with the Class I allele B*27. Since then, AS has been the target of intense research and an enormous amount of information has been gathered about this disease. Now it is known that AS is. | CLINICAL AND MOLECULAR ADVANCES IN ANKYLOSING SPONDYLITIS Edited by Jacome Bruges-Armas Clinical and Molecular Advances in Ankylosing Spondylitis Edited by Jacome Bruges-Armas Published by InTech Janeza Trdine 9 51000 Rijeka Croatia Copyright 2012 InTech All chapters are Open Access distributed under the Creative Commons Attribution license which allows users to download copy and build upon published articles even for commercial purposes as long as the author and publisher are properly credited which ensures maximum dissemination and a wider impact of our publications. After this work has been published by InTech authors have the right to republish it in whole or part in any publication of which they are the author and to make other personal use of the work. Any republication referencing or personal use of the work must explicitly identify the original source. As for readers this license allows users to download copy and build upon published chapters even for commercial purposes as long as the author and publisher are properly credited which ensures maximum dissemination and a wider impact of our publications. Notice Statements and opinions expressed in the chapters are these of the individual contributors and not necessarily those of the editors or publisher. No responsibility is accepted for the accuracy of information contained in the published chapters. The publisher assumes no responsibility for any damage or injury to persons or property arising out of the use of any materials instructions methods or ideas contained in the book. Publishing Process Manager Ivana Zec Technical Editor Teodora Smiljanic Cover Designer InTech Design Team First published February 2012 Printed in Croatia A free online edition of this book is available at Additional hard copies can be obtained from orders@ Clinical and Molecular Advances in Ankylosing Spondylitis Edited by Jacome Bruges-Armas p. cm. ISBN 978-953-51-0137-6 INTECH open

• Y học thường thức
• Pancreatic Cancer
• Network Centric Understanding
• Systems
• Pancreatic Ductal
• Adenocarcinoma Signalling
• Novel Biomarkers
• BMC Cancer
• Pancreatic carcinoma
• Pancreatic exocrine insufficiency
• Unresectable pancreatic cancer
• Pancreatic enzyme replacement therapy
• Recurrent pancreatic ductal adenocarcinoma
• Recurrent pancreatic cancer
• Metastatic pancreatic cancer
• Gemcitabine nab paclitaxel
• Combination chemotherapy
• Pancreatic ductal adenocarcinoma
• Neoadjuvant chemotherapy
• Perioperative chemotherapy
• Randomized trial
• Pancreatic stellate cells
• Extracellular matrix
• PSC CM induced chemoresistance
• Overall survival
• Pancreatic intraepithelial neoplasia
• Cancer stem cells
• Tumor stroma
• Tumor microenvironment
• Recurrence pattern
• Pancreatic neoplasm
• Pancreatic juice
• Mutation analysis
• Liquid biopsy
• Elderly patient
• Non surgical treatment
• Charlson comorbidity index
• Physical activity
• Life course
• Pancreatic cancer risk
• Life course physical activity
• Differential diagnosis
• Pancreatic head cancer
• Distal cholangiocarcinoma
• Histopathological similarity
• Liver metastases
• Unexpected liver metastasis
• Peritoneal carcinomatosis
• Advanced disease
• Lethal cancers
• Cancer incidence
• Locally advanced pancreatic cancer
• Induction chemotherapy
• Salvage therapy
• Prognostic factor
• Borderline resectable pancreatic cancer
• Neoadjuvant chemoradiotherapy
• Progression of vascular invasion
• Confidence interval
• Cancer stem cell
• Protein kinase C
• Nab paclitaxel
• Lymphoid cell types
• Tumor growth
• Human clinical treatment
• Neoadjuvant therapy
• Anatomically widely spread
• Intensity modulated radiation therapy
• Advanced cancer
• Biliary tract cancer
• Lung cancer
• Multimodal intervention
• Enzyme gamma glutamyltransferase
• Serum gamma glutamyltransferase
• Tumor cell proliferation
• Tumor progression
• Human pancreatic cancer
• Severity assessment
• Animal models
• Murine model of pancreatic cancer
• Non invasive methods compared
• European surgeons
• Hormone sensitive lipase
• Adipose tissue inflammation
• Pancreatic inflammation
• Animal model
• H 1 parvovirus
• Oncolytic virotherapy
• Clinical protocol